Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.33) by 89.39 percent. This is a 86.54 percent increase over losses of $(0.26) per share from the same period last year.
2022’s Worst Performing Hedge Fund Saw Negative 56% Returns, Has These Stocks To Blame
Last year was one of the worst years for equities, with all three major indexes having their worst year since 2008, cutting a three-year winning streak.
